EMAIL THIS PAGE TO A FRIEND

Respiratory research

Bifidobacterium breve and Lactobacillus rhamnosus treatment is as effective as budesonide at reducing inflammation in a murine model for chronic asthma.


PMID 24735374

Abstract

Asthma is estimated to affect as many as 300 million people worldwide and its incidence and prevalence are rapidly increasing throughout the world, especially in children and within developing countries. Recently, there has been a growing interest in the use of potentially beneficial bacteria for allergic diseases. This study is aimed at exploring the therapeutic effects of long-term treatment with two different beneficial bacterial strains (Bifidobacterium breve M-16 V and Lactobacillus rhamnosus NutRes1) and a glucocorticoid (budesonide), as a reference treatment, on inflammatory response in a murine model for chronic allergic asthma. To mimic the chronic disease in asthmatic patients, we used the murine ovalbumin-induced asthma model combined with prolonged allergen exposure. Airway function; pulmonary airway inflammation; airway remodelling, mRNA expression of pattern recognition receptors, Th-specific cytokines and transcription factors in lung tissue; mast cell degranulation; in vitro T cell activation; and expression of Foxp3 in blood Th cells were examined. Lactobacillus rhamnosus reduced lung resistance to a similar extent as budesonide treatment in chronically asthmatic mice. Pulmonary airway inflammation, mast cell degranulation, T cell activation and airway remodelling were suppressed by all treatments. Beneficial bacteria and budesonide differentially modulated the expression of toll-like receptors (TLRs), nod-like receptors (NLRs), cytokines and T cell transcription factors. Bifidobacterium breve induced regulatory T cell responses in the airways by increasing Il10 and Foxp3 transcription in lung tissue as well as systemic by augmenting the mean fluorescence intensity of Foxp3 in blood CD4+ T cells. These findings show that Bifidobacterium breve M-16 V and Lactobacillus rhamnosus NutRes1 have strong anti-inflammatory properties that are comparable to budesonide and therefore may be beneficial in the treatment of chronic asthma.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A6435
Aluminum potassium sulfate dodecahydrate, BioReagent, suitable for insect cell culture
AlKO8S2 · 12H2O
31242
Aluminum potassium sulfate dodecahydrate, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.5%
AlKO8S2 · 12H2O
237086
Aluminum potassium sulfate dodecahydrate, ACS reagent, ≥98%
AlKO8S2 · 12H2O
A7210
Aluminum potassium sulfate dodecahydrate, BioXtra, ≥98.0%
AlKO8S2 · 12H2O
A9434
Ammonium chloride, for molecular biology, suitable for cell culture, ≥99.5%
H4ClN
09718
Ammonium chloride, BioUltra, for molecular biology, ≥99.5% (AT)
H4ClN
254134
Ammonium chloride, 99.998% trace metals basis
H4ClN
326372
Ammonium chloride, 99.99% trace metals basis
H4ClN
PHR1327
Ammonium chloride, Pharmaceutical Secondary Standard; Certified Reference Material
H4ClN
09724
Ammonium chloride, tested according to Ph Eur
H4ClN
09683
Ammonium ion solution for ISE, 0.1 M NH4+, analytical standard (for ion-selective electrodes)
H4ClN
09685
Ammonium ion solution for ISE, 1000 mg/kg N, analytical standard (for ion-selective electrodes)
H4ClN
B7777
Budesonide, ≥99%
C25H34O6
PHR1178
Budesonide, Pharmaceutical Secondary Standard; Certified Reference Material
C25H34O6
B1157300
Budesonide, European Pharmacopoeia (EP) Reference Standard
C25H34O6
RAB0054
Human MCP-1 / CCL2 ELISA Kit, for serum, plasma, cell culture supernatant and urine
RAB0055
Mouse MCP-1 / CCL2 ELISA Kit, for serum, plasma and cell culture supernatant
RAB0056
Mouse MCP-1 / CCL2 ELISA Kit, for cell and tissue lysates
RAB0057
Rat MCP-1 / CCL2 ELISA Kit, for serum, plasma and cell culture supernatant
RAB0058
Rat MCP-1 / CCL2 ELISA Kit, for cell and tissue lysates